Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 3/20 | 0.38 |
| ▸ | F7 | P08709 | 3/20 | 0.38 |
| ▸ | F3 | P13726 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 3/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209218 | 1.00 | TP53 (0.39) | TP53MAPTF2F7F3 | |
| SCHEMBL3832813 | 0.96 | CA12 (0.38) | TP53MAPTF2F7F3 | |
| SCHEMBL2358520 | 0.85 | ELANE (0.42) | ELANECASP1 | |
| SCHEMBL3852283 | 0.85 | ELANE (0.42) | ELANECASP1 | |
| SCHEMBL2212579 | 0.85 | ELANE (0.49) | ELANE | |
| SCHEMBL2212581 | 0.85 | ELANE (0.49) | ELANE | |
| SCHEMBL4777094 | 0.83 | CA12 (0.34) | TP53MAPTLMNABIRC2MMP2 | |
| SCHEMBL2211912 | 0.82 | ELANE (0.43) | TP53ELANECMA1 | |
| SCHEMBL3832817 | 0.79 | TRPV1 (0.40) | F2F7F3LMNAELANE | |
| SCHEMBL2209970 | 0.79 | F7 (0.49) | TP53MAPTF2F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099769-B1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | claimed |
| EP-2099769-A1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2009-09-16 | — | — | EP | claimed |
| WO-2008073305-A1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | claimed |
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | TP53 23/4885MAPT 520/4885F2 4184/4885 |
| US-20100249405-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | TP53 23/4885MAPT 520/4885F2 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.